Supernus Pharmaceuticals Inc. and Indivior Pharmaceuticals Inc. have entered into a definitive merger agreement structured as an all-stock, tax-free reorganization. Under the terms of the agreement, Supernus shareholders will receive 1.5401 Indivior shares for each Supernus share held at closing. Following completion, Indivior shareholders are expected to hold approximately 56.5% of the combined company, with Supernus shareholders retaining approximately 43.5%.

The combined entity will operate under the Supernus Inc. name and continue trading on Nasdaq under the ticker symbol "SUPN." Closing is expected in the fourth quarter of 2026, subject to shareholder approvals from both companies, regulatory clearances, and the satisfaction of customary closing conditions.

Immediately prior to closing, Indivior shareholders will receive a special cash dividend totaling $1 billion. Approximately $650 million of this distribution will be funded through a term loan facility provided by Citibank, with the remainder drawn from existing cash on hand.

The parties project the combined company will achieve approximately $2.2 billion in pro forma net revenue and $888 million in adjusted EBITDA on an annualized basis. Management anticipates approximately $125 million in annual cost synergies from the combination.

The merged portfolio will encompass eleven distinct commercial products spanning psychiatry, neurology, and addiction treatment, creating one of the more diversified specialty CNS platforms among mid-cap pharmaceutical companies.

The merger is structured as a merger of equals rather than a conventional acquirer-target acquisition. The eight-member board of the combined company will include four directors from each party, reflecting the negotiated balance of ownership and governance. The fixed exchange ratio means that fluctuations in either company's market capitalization between signing and closing will be borne by the respective shareholder bases.

Key closing milestones include shareholder approvals from both companies, the effectiveness of a Form S-4 registration statement with the SEC, and confirmation that the transaction qualifies as a tax-free reorganization under U.S. federal income tax law. The $1 billion special dividend and its associated debt financing introduce additional structural complexity that will require careful coordination with the merger timeline.

Due diligence and integration planning should prioritize FDA regulatory status and pipeline risk for each product, product liability exposure, government healthcare program rebate obligations, controlled substances compliance under the DEA framework, patent term and exclusivity schedules, and the resolution of any legacy opioid-related litigation involving Indivior's historical product portfolio.

This summary is based on publicly available information as of August 3, 2026. It is provided for informational purposes only and does not constitute legal advice.